MPO/NLRP3轴介导的中性粒细胞胞外诱捕网对糖尿病神经病理性疼痛的影响
本研究在链脲佐菌素诱导的糖尿病周围神经病变小鼠模型中,通过定量蛋白质组学发现髓过氧化物酶显著上调并与NETs通路富集相关;使用Cl-amidine抑制PAD4介导的NETs形成后,小鼠疼痛敏感性显著减轻,NETs相关蛋白及促炎细胞因子表达下降,NLRP3相关蛋白及IL-1β、IL-18水平降低。
要点
- DPN小鼠中MPO显著上调,并与NETs通路富集相关。
- 抑制PAD4介导的NETs形成可减轻疼痛 hypersensitivity。
- Cl-amidine降低NLRP3相关蛋白及IL-1β、IL-18水平。
核心结论
- MPO/NLRP3轴介导NETs驱动的神经炎症在DPN中起重要作用。
- 联合清除NETs与抑制炎症小体可能成为潜在治疗策略。
研究设计与样本
- 采用链脲佐菌素(STZ)诱导的DPN小鼠模型,进行定量蛋白质组学分析与功能验证。
- 使用Cl-amidine药理学抑制PAD4介导的NETs形成。
- 通过STRING构建蛋白互作网络并对关键炎症通路进行实验验证。
主要发现
- DPN小鼠MPO显著上调(45.0 ± 1.41 vs 28.3 ± 3.47;P = .002)。
- 富集分析显示与NETs通路强相关(fold enrichment = 5.03;P = .021)。
- Cl-amidine随时间显著减轻痛觉过敏,重复测量ANOVA组×时间交互P < .001。
- 第3周后测PWT升高(0.450 ± 0.170 g vs 0.230 ± 0.170 g,P = .011),HWT延长(16.5 ± 3.76秒 vs 11.4 ± 3.76秒;P = .002)。
- Cl-amidine降低NETs相关蛋白、促炎细胞因子、NLRP3相关蛋白及IL-1β和IL-18水平。
关键数值与推荐
- PPI分析检测到MPO与NLRP3关联(textmining: 0.465),共表达支持(0.042)。
临床怎么用
- 提示NETs清除联合炎症小体抑制可能作为DPN疼痛的潜在治疗方向。
局限性
- 研究仅基于小鼠模型,临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetic peripheral neuropathy (DPN) is a debilitating diabetic complication with progressive nerve damage and chronic pain. The limited efficacy of current treatments reflects the incomplete understanding of its underlying mechanisms, particularly the role of neutrophil extracellular traps (NETs) in neuroinflammation. METHODS: Using a streptozotocin (STZ)-induced DPN mouse model, we conducted quantitative proteomic analysis with functional validation. Pharmacological inhibition of protein-arginine deiminase type-4 (PAD4)-mediated NETs formation was achieved using Cl-amidine. Protein interaction networks were constructed via STRING and experimentally validated for key inflammatory pathways. RESULTS: Proteomic analysis revealed a significant upregulation of myeloperoxidase (MPO) in DPN mice (45.0 ± 1.41 vs 28.3 ± 3.47; P = .002), with enrichment analysis indicating a strong association with the NETs pathway (fold enrichment = 5.03; P = .021). Functional assays showed that Cl-amidine significantly attenuated pain hypersensitivity over time, with repeated measures analysis of variance (ANOVA) confirming a significant group × time interaction ( P < .001). Post hoc analysis demonstrated increased paw withdrawal threshold (PWT: 0.450 ± 0.170 g vs 0.230 ± 0.170 g, P = .011) and hot withdrawal latency (HWT: 16.5 ± 3.76 seconds vs 11.4 ± 3.76 seconds; P = .002) at week 3. Cl-amidine also markedly reduced the expression of NETs-related proteins and proinflammatory cytokines. Protein-protein interaction (PPI) analysis detected MPO-NLR family pyrin domain containing 3 (NLRP3) association (textmining: 0.465) with ancillary co-expression support (0.042), consistent with their shared roles in inflammatory pathways. Notably, Cl-amidine treatment significantly decreased NLRP3-related proteins along with interleukin (IL)-1β and IL-18 levels. CONCLUSIONS: This study is the first to reveal that the MPO/NLRP3 axis mediates NETs-driven neuroinflammation in DPN. The findings provide molecular insights into DPN pathogenesis and suggest combined NETs clearance with inflammasome inhibition as a potential therapeutic strategy.
引用
- Pan Y, Cao Y, Chen X, et al. Influence of MPO/NLRP3 Axis-Mediated Neutrophil Extracellular Traps on Diabetic Neuropathic Pain in a Mouse Model. Anesth Analg. 2025. PMID: 41289599. doi:10.1213/ANE.0000000000007814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。